Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ozanimod study in moderately to severely active ulcerative colitis
jRCT2021220013Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in autoimmune colitis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of participants who achieve clinical remission. Started Jul 2022; status: recruiting.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2021220013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220013.